Disitamab Vedotin (RC48)

DRUG6 trials

Sponsors

The First Affiliated Hospital with Nanjing Medical University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Peking University First Hospital, West China Hospital, Zhiquan Hu

Conditions

HER2 + Breast CancerHER2-low Breast CancerMIBCUpper Tract Urothelial CarcinomaUrinary Bladder NeoplasmsmCRPC

Phase 2

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

RecruitingNCT07065435

The First Affiliated Hospital with Nanjing Medical UniversityHER2 + Breast Cancer

Start: 2024-01-01End: 2026-01-01Target: 74Updated: 2025-07-15

Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer：a Phase II Study

RecruitingNCT07093866

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolmCRPC

Start: 2025-07-20End: 2027-12-30Target: 20Updated: 2025-07-30

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

RecruitingNCT07446452

The First Affiliated Hospital with Nanjing Medical UniversityHER2-low Breast Cancer

Start: 2024-01-01End: 2027-01-01Target: 37Updated: 2026-03-03

Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma

Not yet recruitingNCT07498907

Peking University First HospitalUpper Tract Urothelial Carcinoma

Start: 2026-05-01End: 2034-03-01Target: 192Updated: 2026-03-27

HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC

Not yet recruitingNCT07608224

West China HospitalUrinary Bladder Neoplasms

Start: 2026-06-20End: 2030-12-31Target: 240Updated: 2026-05-27

Phase 3

Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC

RecruitingNCT07693959

Start: 2026-07-01End: 2029-07-01Target: 170Updated: 2026-07-09